Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Beats Expectations By $0.02 EPS
by Danessa Lincoln · The Markets DailyNeumora Therapeutics (NASDAQ:NMRA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02, FiscalAI reports.
Neumora Therapeutics Stock Performance
Neumora Therapeutics stock opened at $0.43 on Monday. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. Neumora Therapeutics has a 52 week low of $0.32 and a 52 week high of $3.65. The stock has a 50-day moving average price of $0.60 and a 200 day moving average price of $1.70. The company has a market capitalization of $80.59 million, a price-to-earnings ratio of -0.35 and a beta of 3.12.
Wall Street Analyst Weigh In
Several research firms have recently commented on NMRA. HC Wainwright reiterated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th. Finally, Weiss Ratings raised Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Neumora Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $6.57.
View Our Latest Report on NMRA
Insider Activity
In related news, insider Daljit Singh Aurora sold 67,741 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $1.51, for a total transaction of $102,288.91. Following the completion of the transaction, the insider owned 48,750 shares of the company’s stock, valued at $73,612.50. This trade represents a 58.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 307,127 shares of company stock worth $481,160 over the last three months. Company insiders own 26.94% of the company’s stock.
About Neumora Therapeutics
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease. The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.
Read More
- Five stocks we like better than Neumora Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?